These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20648074)

  • 21. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
    Montero JA; Ruiz-Moreno JM; Correa ME
    Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 23. Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema.
    Giuliari GP; Guel DA; Gonzalez VH
    Curr Diabetes Rev; 2009 Feb; 5(1):33-8. PubMed ID: 19199896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on nonsurgical therapy for diabetic macular edema.
    Witkin AJ; Brown GC
    Curr Opin Ophthalmol; 2011 May; 22(3):185-9. PubMed ID: 21427573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
    Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
    Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Molecular targeting therapy for diabetic retinopathy].
    Nakao S; Yoshida S; Enaida H; Ishibashi T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():628-46. PubMed ID: 23513915
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
    Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy.
    Kwon SH; Shin JP; Kim IT; Park DH
    Ophthalmology; 2015 May; 122(5):968-75. PubMed ID: 25687026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 31. Diabetic retinopathy: current and new treatment options.
    Giuliari GP
    Curr Diabetes Rev; 2012 Jan; 8(1):32-41. PubMed ID: 22352446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of ocular neovascularization: promises and potential problems.
    van Wijngaarden P; Coster DJ; Williams KA
    JAMA; 2005 Mar; 293(12):1509-13. PubMed ID: 15784876
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of sight-threatening diabetic retinopathy].
    Grauslund J
    Ugeskr Laeger; 2018 Jul; 180(31):. PubMed ID: 30064622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
    Isaacs TW; Barry C
    Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranibizumab for diabetic retinopathy.
    Rodriguez-Fontal M; Alfaro V; Kerrison JB; Jablon EP
    Curr Diabetes Rev; 2009 Feb; 5(1):47-51. PubMed ID: 19199898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.
    Yamaji H; Shiraga F; Shiragami C; Nomoto H; Fujita T; Fukuda K
    Arch Ophthalmol; 2011 Jan; 129(1):106-7. PubMed ID: 21220639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.